Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience

Hyperleukocytosis in pediatric acute leukemia is associated with increased morbidity and mortality and at present there is no consensus on the use of leukapheresis (LPH) for its management. Our aim was to review characteristics and outcomes of newly diagnosed leukemia patients with hyperleukocytosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Sandra Renee, Rahrig, April, Saraf, Amanda J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024808/
https://www.ncbi.nlm.nih.gov/pubmed/35455547
http://dx.doi.org/10.3390/children9040503
_version_ 1784690698829692928
author Jones, Sandra Renee
Rahrig, April
Saraf, Amanda J.
author_facet Jones, Sandra Renee
Rahrig, April
Saraf, Amanda J.
author_sort Jones, Sandra Renee
collection PubMed
description Hyperleukocytosis in pediatric acute leukemia is associated with increased morbidity and mortality and at present there is no consensus on the use of leukapheresis (LPH) for its management. Our aim was to review characteristics and outcomes of newly diagnosed leukemia patients with hyperleukocytosis (HL) comparing those who received LPH and those who did not. An IRB approved retrospective case control study reviewed data from a single institution over a 10 year period. At our institution, LPH was used in 8 of 62 (13%) patients with hyperleukocytosis with minimal complications. Mean leukocyte count in patients who received LPH versus those who did not was 498 k cells/mm(3) and 237 k cells/mm(3), respectively. Patients who had symptoms of neurologic (63 vs. 17%) or pulmonary leukostasis (75 vs. 17%) were more likely to have undergone leukapheresis. The time from presentation to the initiation of chemotherapy was not different between those who received LPH and those who did not (mean of 35 h vs. 34 h). There was one death in the LPH group, that was the result of neurologic sequelae of hyperleukocytosis and not LPH itself. The use of LPH in patients with hyperleukocytosis is safe, well tolerated and does not alter time to chemotherapy at our institution.
format Online
Article
Text
id pubmed-9024808
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90248082022-04-23 Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience Jones, Sandra Renee Rahrig, April Saraf, Amanda J. Children (Basel) Article Hyperleukocytosis in pediatric acute leukemia is associated with increased morbidity and mortality and at present there is no consensus on the use of leukapheresis (LPH) for its management. Our aim was to review characteristics and outcomes of newly diagnosed leukemia patients with hyperleukocytosis (HL) comparing those who received LPH and those who did not. An IRB approved retrospective case control study reviewed data from a single institution over a 10 year period. At our institution, LPH was used in 8 of 62 (13%) patients with hyperleukocytosis with minimal complications. Mean leukocyte count in patients who received LPH versus those who did not was 498 k cells/mm(3) and 237 k cells/mm(3), respectively. Patients who had symptoms of neurologic (63 vs. 17%) or pulmonary leukostasis (75 vs. 17%) were more likely to have undergone leukapheresis. The time from presentation to the initiation of chemotherapy was not different between those who received LPH and those who did not (mean of 35 h vs. 34 h). There was one death in the LPH group, that was the result of neurologic sequelae of hyperleukocytosis and not LPH itself. The use of LPH in patients with hyperleukocytosis is safe, well tolerated and does not alter time to chemotherapy at our institution. MDPI 2022-04-02 /pmc/articles/PMC9024808/ /pubmed/35455547 http://dx.doi.org/10.3390/children9040503 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jones, Sandra Renee
Rahrig, April
Saraf, Amanda J.
Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience
title Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience
title_full Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience
title_fullStr Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience
title_full_unstemmed Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience
title_short Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience
title_sort leukapheresis in pediatric acute leukemia with hyperleukocytosis: a single-center experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024808/
https://www.ncbi.nlm.nih.gov/pubmed/35455547
http://dx.doi.org/10.3390/children9040503
work_keys_str_mv AT jonessandrarenee leukapheresisinpediatricacuteleukemiawithhyperleukocytosisasinglecenterexperience
AT rahrigapril leukapheresisinpediatricacuteleukemiawithhyperleukocytosisasinglecenterexperience
AT sarafamandaj leukapheresisinpediatricacuteleukemiawithhyperleukocytosisasinglecenterexperience